JP6338375B2 - 腸球菌病原体の新規の抗原、並びに治療法及び/又は予防法のためのワクチン成分としてのその使用 - Google Patents
腸球菌病原体の新規の抗原、並びに治療法及び/又は予防法のためのワクチン成分としてのその使用 Download PDFInfo
- Publication number
- JP6338375B2 JP6338375B2 JP2013537136A JP2013537136A JP6338375B2 JP 6338375 B2 JP6338375 B2 JP 6338375B2 JP 2013537136 A JP2013537136 A JP 2013537136A JP 2013537136 A JP2013537136 A JP 2013537136A JP 6338375 B2 JP6338375 B2 JP 6338375B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- orf13
- bacterial
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229960005486 vaccine Drugs 0.000 title claims description 19
- 230000001225 therapeutic effect Effects 0.000 title claims description 10
- 108091007433 antigens Proteins 0.000 title description 17
- 102000036639 antigens Human genes 0.000 title description 17
- 238000000034 method Methods 0.000 title description 17
- 239000000427 antigen Substances 0.000 title description 16
- 244000052769 pathogen Species 0.000 title description 6
- 230000000069 prophylactic effect Effects 0.000 title description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 31
- 102000004169 proteins and genes Human genes 0.000 claims description 29
- 241000194032 Enterococcus faecalis Species 0.000 claims description 28
- 229940032049 enterococcus faecalis Drugs 0.000 claims description 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 241000194031 Enterococcus faecium Species 0.000 claims description 19
- 239000012634 fragment Substances 0.000 claims description 15
- 241000191967 Staphylococcus aureus Species 0.000 claims description 13
- 208000035143 Bacterial infection Diseases 0.000 claims description 10
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 241000295644 Staphylococcaceae Species 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 6
- 206010014889 Enterococcal infections Diseases 0.000 claims description 6
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 108010065152 Coagulase Proteins 0.000 claims description 4
- 201000009906 Meningitis Diseases 0.000 claims description 4
- 206010034133 Pathogen resistance Diseases 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 208000031729 Bacteremia Diseases 0.000 claims description 3
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- 206010062255 Soft tissue infection Diseases 0.000 claims description 3
- 206010048038 Wound infection Diseases 0.000 claims description 3
- 206010034674 peritonitis Diseases 0.000 claims description 3
- 208000019206 urinary tract infection Diseases 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 206010014666 Endocarditis bacterial Diseases 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 208000009361 bacterial endocarditis Diseases 0.000 claims description 2
- 201000007119 infective endocarditis Diseases 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 239000013612 plasmid Substances 0.000 description 24
- 108010046504 Type IV Secretion Systems Proteins 0.000 description 21
- 210000002966 serum Anatomy 0.000 description 16
- 101000818108 Acholeplasma phage L2 Uncharacterized 81.3 kDa protein Proteins 0.000 description 12
- 101000912350 Haemophilus phage HP1 (strain HP1c1) DNA N-6-adenine-methyltransferase Proteins 0.000 description 12
- 101000790844 Klebsiella pneumoniae Uncharacterized 24.8 kDa protein in cps region Proteins 0.000 description 12
- 238000003556 assay Methods 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- 241000193998 Streptococcus pneumoniae Species 0.000 description 6
- 231100000225 lethality Toxicity 0.000 description 6
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241000192125 Firmicutes Species 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 241000884324 Enterococcus faecalis DS5 Species 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 101000748061 Acholeplasma phage L2 Uncharacterized 16.1 kDa protein Proteins 0.000 description 3
- 101000947615 Clostridium perfringens Uncharacterized 38.4 kDa protein Proteins 0.000 description 3
- 101000964391 Enterococcus faecalis UPF0145 protein Proteins 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 101000748063 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 11.1 kDa protein in rep-hol intergenic region Proteins 0.000 description 3
- 101000790840 Klebsiella pneumoniae Uncharacterized 49.5 kDa protein in cps region Proteins 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 108091006112 ATPases Proteins 0.000 description 2
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 2
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- 241000186781 Listeria Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 108700022034 Opsonin Proteins Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010041925 Staphylococcal infections Diseases 0.000 description 2
- 101000936711 Streptococcus gordonii Accessory secretory protein Asp4 Proteins 0.000 description 2
- 101000912941 Streptococcus gordonii DegV domain-containing protein Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 244000000059 gram-positive pathogen Species 0.000 description 2
- 230000000521 hyperimmunizing effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000014207 opsonization Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- ZZIZZTHXZRDOFM-XFULWGLBSA-N tamsulosin hydrochloride Chemical compound [H+].[Cl-].CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 ZZIZZTHXZRDOFM-XFULWGLBSA-N 0.000 description 2
- 239000000304 virulence factor Substances 0.000 description 2
- 230000007923 virulence factor Effects 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 101100226888 Phomopsis amygdali PaAT-2 gene Proteins 0.000 description 1
- 241001495397 Rickettsia sibirica Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000187398 Streptomyces lividans Species 0.000 description 1
- 102400000368 Surface protein Human genes 0.000 description 1
- 101710110895 Uncharacterized 7.3 kDa protein in cox-rep intergenic region Proteins 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000007924 bacterial virulence factor Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000000625 opsonophagocytic effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000003158 yeast two-hybrid assay Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
MSYYFEIRIILPEEENQFLNRKLSKSELSEVTHYLQQKTSRGIPVKFRVGIFRVEDQTKIMSVTLNTKNTKETDVINLLLNRVTDQHVLVYLNEPTEPTLNTQELNRQELKTSNERQEIPQTEIPTETVNEPSVIKKISKKNQAKQTNSRKESLSESITKKNVPKIHLFISILTLFIVLLIGISVIQQVQLQSVKKESELLEEQIERVKETDISQSKIDTFGRYFLTYYFSQEKNQENYQSSLRTYVSEKVDISDWKALGKTLKSVNYYGSEQTKKGYSVEYLLNVSVDNRSKMQKITFEVEPTKNGFLVTTQPKLTDFSFN(配列番号1)
Orf13は322個のアミノ酸からなり(分子量37479.76Da)、pIは8.86である。orf13を、アミノ末端7×Hisタグを有するエシェリヒア・コリ発現ベクターにクローニングし(非特許文献5)、過剰発現させ、アフィニティークロマトグラフィーによって精製した(Goessweiner-Mohr, N., Grohmann, E., and Keller, W.、未発表データ)。精製タンパク質を使用してウサギを免疫化した。ORF7及びORF10に対して同様に(正:similarly)調製した血清を対照として使用した。
1. Abajy, M. Y. Molekularbiologische und biochemische Untersuchungen zum Typ IV Sekretion-aehnlichen System (T4SLS) des konjugativen Antibiotikaresistenzplasmids pIP501 in Enterococcus faecalis. (2007). PhD Thesis, TU Berlin, Berlin.
2. Abajy, M. Y., Kopec, J., Schiwon, K., Burzynski, M., Doering, M., Bohn, C., and Grohmann, E. (2007). A type IV-secretion-like system (T4SLS) is required for conjugative DNA transport of plasmid pIP501 with broad host range in Gram-positive bacteria J. Bacteriol. 189: 2487-2496.
3. Alvarez-Martinez, C. E., and Christie, P. J. (2009). Biological diversity of prokaryotic type IV secretion systems. Microbiol. Mol. Biol. Rev. 73: 775-808.
4. Grohmann, E., Muth, G., and Espinosa, M. (2003). Conjugative plasmid transfer in Gram-positive bacteria. Microbiol. Mol. Biol. Rev. 67: 277-301.
5. Grohmann, E. (2006). Mating cell-cell channels in conjugating bacteria. In Cell-Cell Channels (eds. Baluska, F., Volkmann, D., and Barlow, P.W.), Landes Biosciences, Georgetown, Texas, pp. 21-38. ISBN: 1-58706-065-5.
6. Kurenbach, B., Bohn, C., Prabhu, J., Abudukerim, M., Szewzyk, U., and Grohmann, E. (2003). Intergeneric transfer of the Enterococcus faecalis plasmid pIP501 to Escherichia coli and Streptomyces lividans and sequence analysis of its tra region. Plasmid 50: 86-93.
7. Schaberg, D.R., Clewell, D. B., and Glatzer, L. 1982. Conjugative transfer of R-plasmids from Streptococcus faecalis to Staphylococcus aureus. Antimicrob. Agents Chemother. 22:204-207.
8. Zhu, W., Murray, P.R., Huskins, W.C., Jernigan, J.A., McDonald, L.C., Clark, N.C., Anderson, K.F., McDougal, L.K., Hageman, J.C., Olsen-Rasmussen, M., Frace, M., Alangaden, G.J., Chenoweth, C., Zervos, M.J., Robinson-Dunn, B., Schreckenberger, P.C., Reller, L.B., Rudrik, J.T. and Patel, J.B. Dissemination of an Enterococcus Inc18-Like vanA Plasmid Associated with Vancomycin-Resistant Staphylococcus aureus, Antimicrob. Agents Chemother. 54 (10), 4314-4320 (2010).
9. Theilacker C, Sanchez-Carballo P, Toma I, Fabretti F, Sava I, Kropec A, Holst O, Huebner J. Glycolipids are involved in biofilm accumulation and prolonged bacteraemia in Enterococcus faecalis. Mol Microbiol. 2009 Feb;71(4):1055-69.
Claims (8)
- 疾患の治療に使用される単離ペプチドと、薬学的に許容可能な担体、アジュバント及び/又は希釈剤とを含む医薬組成物であって、
ここで、前記単離ペプチドが、
a)配列番号1に表されるアミノ酸配列からなるOrf13タンパク質に結合する抗体又はその断片
から選択される、医薬組成物。
- 前記単離ペプチドが、チャネル形成成分である、請求項1に記載の医薬組成物。
- 前記抗体又はその断片がscFV断片又はFab断片から選択される、請求項1に記載の医薬組成物。
- ワクチンである、請求項1に記載の医薬組成物。
- 少なくとも1つのサイトカインを更に含む、請求項1〜4のいずれか一項に記載の医薬組成物。
- ワクチンが筋肉内経路、皮下経路又は吸入経路による投与のために配合される、請求項1〜4のいずれか一項に記載の医薬組成物。
- 細菌感染症、腸球菌感染症、尿路感染症、菌血症、細菌性心内膜炎、腹膜炎、創傷感染症及び軟部組織感染症、髄膜炎、並びに肺炎から選択される細菌性疾患又は細菌性病態の予防的治療又は治療的治療のための、請求項1〜6のいずれか一項に記載の医薬組成物。
- 前記細菌が腸球菌、ブドウ球菌又は連鎖球菌、エンテロコッカス・フェシウム、エンテロコッカス・フェカリス、スタフィロコッカス・アウレウス、コアグラーゼ陰性ブドウ球菌若しくはストレプトコッカス・ピオゲネス、又はそれらの抗生物質耐性株から選択される、請求項7に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10190167.6 | 2010-11-05 | ||
EP10190167.6A EP2450053B1 (en) | 2010-11-05 | 2010-11-05 | Novel antigen of enterococcal pathogens and use thereof as vaccine component for therapy and/or prophylaxis |
PCT/EP2011/069363 WO2012059556A1 (en) | 2010-11-05 | 2011-11-03 | Novel antigen of enterococcal pathogens and use thereof as vaccine component for therapy and/or prophylaxis |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014505016A JP2014505016A (ja) | 2014-02-27 |
JP6338375B2 true JP6338375B2 (ja) | 2018-06-06 |
Family
ID=43528337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013537136A Expired - Fee Related JP6338375B2 (ja) | 2010-11-05 | 2011-11-03 | 腸球菌病原体の新規の抗原、並びに治療法及び/又は予防法のためのワクチン成分としてのその使用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20130309264A1 (ja) |
EP (1) | EP2450053B1 (ja) |
JP (1) | JP6338375B2 (ja) |
CA (1) | CA2816913A1 (ja) |
HK (1) | HK1170183A1 (ja) |
WO (1) | WO2012059556A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3415160B1 (en) | 2014-03-04 | 2021-08-18 | Klinikum der Universität München | Polypeptides derived from enterococcus and their use for vaccination and the generation of therapeutic antibodies |
RU2705415C1 (ru) * | 2019-01-10 | 2019-11-07 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) | Способ диагностики стафилококковой абдоминальной хирургической инфекции |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9401689D0 (en) * | 1994-01-28 | 1994-03-23 | Univ Manchester | Diagnosis and treatment of endocarditis |
JPH07238024A (ja) * | 1994-02-25 | 1995-09-12 | Nichinichi Seiyaku Kk | 好中球機能改善剤 |
GB9614274D0 (en) * | 1996-07-06 | 1996-09-04 | Univ Manchester | Treatment and diagnosis of infections of gram positive cocci |
US20050026218A1 (en) | 2003-05-30 | 2005-02-03 | Agencourt Bioscience Corporation | Protein interaction mapping |
JP5371169B2 (ja) * | 2004-09-24 | 2013-12-18 | コンビ株式会社 | 薬剤耐性菌感染防除剤 |
-
2010
- 2010-11-05 EP EP10190167.6A patent/EP2450053B1/en not_active Not-in-force
-
2011
- 2011-11-03 WO PCT/EP2011/069363 patent/WO2012059556A1/en active Application Filing
- 2011-11-03 JP JP2013537136A patent/JP6338375B2/ja not_active Expired - Fee Related
- 2011-11-03 CA CA2816913A patent/CA2816913A1/en not_active Abandoned
- 2011-11-03 US US13/879,750 patent/US20130309264A1/en not_active Abandoned
-
2012
- 2012-11-02 HK HK12111031.4A patent/HK1170183A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HK1170183A1 (zh) | 2013-02-22 |
CA2816913A1 (en) | 2012-05-10 |
WO2012059556A1 (en) | 2012-05-10 |
EP2450053A1 (en) | 2012-05-09 |
US20130309264A1 (en) | 2013-11-21 |
EP2450053B1 (en) | 2016-06-15 |
JP2014505016A (ja) | 2014-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cheng et al. | Novel purification scheme and functions for a C3-binding protein from Streptococcus pneumoniae | |
Wang et al. | The involvement of sortase A in high virulence of STSS-causing Streptococcus suis serotype 2 | |
US11129884B2 (en) | Bacterial vaccine components and uses thereof | |
AU2016201992B2 (en) | Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use | |
KR20080050550A (ko) | 유전자와 단백질들, 및 그들의 사용 | |
Zhou et al. | Adhesion protein ApfA of Actinobacillus pleuropneumoniae is required for pathogenesis and is a potential target for vaccine development | |
TW201113373A (en) | A cytolytic RTX-toxin from gallibacterium anatis | |
Haghighat et al. | Recombinant PBP2a as a vaccine candidate against methicillin-resistant Staphylococcus aureus: Immunogenicity and protectivity | |
EP2474558A1 (en) | New antibiotic containing simulacrum antibody, preparation method and application thereof | |
WO2014179744A1 (en) | Staphylococcus live cell vaccines | |
JP6338375B2 (ja) | 腸球菌病原体の新規の抗原、並びに治療法及び/又は予防法のためのワクチン成分としてのその使用 | |
US20130243779A1 (en) | Peptides protective against e. faecalis, methods and uses relating thereto | |
EP2374466B1 (en) | Protective staphylococcus aureus vaccine based on cell wall-associated proteins | |
Hufnagel et al. | Distribution of four capsular serotypes of Enterococcus faecalis among clinical isolates from different geographical origins and infection sites | |
AU2004201404B2 (en) | Genes and proteins, and their use | |
Yoon | Development of recombinant staphylococcal cytotoxins and superantigens as vaccine candidates against bovine mastitis caused by Staphylococcus aureus | |
CN116761619A (zh) | 用于预防或治疗金黄色葡萄球菌感染性疾病的新型组合物 | |
WO2018093822A1 (en) | Chimeric antibodies comprising binding domains of phage lysins, bacterial autolysins, bacteriocins, and phage tail or tail fibers | |
Lindahl et al. | Enterococcus faecalis Infection-Derived | |
Brown et al. | CD4 T Cell Antigens from Staphylococcus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A072 | Dismissal of procedure [no reply to invitation to correct request for examination] |
Free format text: JAPANESE INTERMEDIATE CODE: A072 Effective date: 20140108 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20141020 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151207 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160307 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160324 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160502 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161018 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170117 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170627 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170814 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20170821 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180117 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180412 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180508 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6338375 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |